The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | Why is personalized medicine important for CLL?
Petra Langerbeins, MD of University of Cologne, Cologne, Germany talks about personalized medicine for chronic lymphocytic leukemia (CLL). Dr Langerbeins believes that personalized medicine will be important for CLL as it is a very heterogenous disease, ranging from patients who will never progress to patients who develop Richter’s transformation. Therefore, profiling patients will become more and more interesting according to Dr Langerbeins.
Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
